We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi Cancer Drug Iniparib Misses Primary Endpoints in Phase III
Sanofi Cancer Drug Iniparib Misses Primary Endpoints in Phase III
February 2, 2011
Sanofi-Aventis’ breast cancer drug iniparib failed to meet co-primary endpoints of overall survival and progression-free survival in a Phase III trial for metastatic triple-negative breast cancer, a particularly aggressive form of the disease.